Barclays lowered the firm’s price target on Zimmer Biomet (ZBH) to $112 from $118 and keeps an Underweight rating on the shares. The firm updated its projections to be in-line with Zimmer’s 2025 outlook.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Zimmer Biomet’s Strategic Growth Amid Challenges
- Zimmer Biomet price target lowered to $107 from $115 at Deutsche Bank
- Zimmer Biomet price target lowered to $125 from $130 at RBC Capital
- Zimmer Biomet price target lowered to $119 from $126 at Raymond James
- Zimmer Biomet price target lowered to $130 from $138 at Baird